Skip to content
Open in App
Acurx Pharmaceuticals LLC logo

Acurx Pharmaceuticals LLC

web2

Acurx Pharmaceuticals is a clinical-stage biotechnology company developing antibiotics for diff...

Symbol ยท ACXP
Company profile

About

Acurx Pharmaceuticals is a clinical-stage biotechnology company developing antibiotics for difficult bacterial infections, including infections caused by organisms resistant to existing treatments. Formerly organized as Acurx Pharmaceuticals LLC, the business converted into a Delaware corporation in 2021 and now operates as Acurx Pharmaceuticals Incorporated. Its lead investigational antibiotic, ibezapolstat, is being developed for infections caused by Clostridioides difficile, which can produce severe diarrhea and intestinal inflammation. The compound targets bacterial DNA polymerase IIIC, an enzyme involved in DNA replication. Other early research programs investigate compounds against Gram-positive pathogens, while ibezapolstat remains in clinical development without marketing approval.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

ExchangeNasdaqPrimary symbol: ACXP
Expert coverage

Acurx Pharmaceuticals LLC profile.

Orbitrum research

Expert coverage

No published expert evaluations are available for this project yet.

Orbitrum Academy

Learn how to read a project assessment